In certain cases, particularly in patients with long-standing diabetes, insulin therapy may become the mainstay or even an essential approach to managing blood glucose levels
1 The main patent for GLP-1 will expire in the early 2030s, making generic equivalents available
27 ) or AAV-hSyn-GFP (as control
Comparisons of metabolite levels between individuals with autism and typically developed (TD) Glu levels were significantly increased in the ACC in adults with autism compared to TD subjects (12.93 [1.27] for the autism group, 12.07 [1.26] for the TD group, t = 2.08, p = 0.045), Gln (2.97 [0.39] for the autism group, 2.70 [0.41] for the TD group, t = 2.09, p = 0.044), and mI (8.42 [1.03] for the autism group, 7.57 [1.27] for the TD group
2 PubMed (BPC-157 angiogenesis)BPC-157 and angiogenic / cytoprotective effects reported in rodent injury models
GLP-1 side effects should settle down over time, not spiral into bigger problems